|Composition||Voglibose 0.3/0.2 mg|
|Mechanism of Action||
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.
Absorption: voglibose is poorly absorbed after oral administration. However, systematic adverse effects have been observed.
Metabolism: the metabolism of voglibose in liver is negligible
Excretion: The renal excretion is negligible and plasma concentations after oral dose have been undetectable.
Flatulence; abdominal distension; diarrhoea; pain; skin reactions;
hypoglycemia; increased LFT.
Potentially Fatal: Hepatotoxicity
History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 yr; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose).
Adult: 200-300 mcg Thrice a day.
Elderly: Initiate at lower doses.